SCHEMBL547544

SCHEMBL547544

C1=CSSC=N1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1450836 0.54
Ethyne SCHEMBL9248565 0.44
SCHEMBL5134172 0.42
SCHEMBL1465460 0.42
SCHEMBL890278 0.39
SCHEMBL561897 0.37
SCHEMBL26660960 0.34
SCHEMBL13719381 0.34
SCHEMBL6559802 0.28
SCHEMBL16553398 0.28

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022122668-A1 COMBINED INHIBITION OF AMINO ACID TRANSPORTERS FOR INHIBITING HUMAN PLASMACYTOID DENDRITIC CELL ACTIVITY DURING AUTOIMMUNITY MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2022-06-16 WO claimed
EP-4008330-A1 COMBINED INHIBITION OF AMINO ACID TRANSPORTERS FOR INHIBITING HUMAN PLASMACYTOID DENDRITIC CELL ACTIVITY DURING AUTOIMMUNITY Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2022-06-08 EP claimed
EP-3484462-B1 5-HYDROXYTRYPTAMINE 1B RECEPTOR-STIMULATING AGENT FOR SKIN AND/OR HAIR REPAIR PASTEUR INSTITUT (FR) 2022-12-14 EP disclosed
WO-2022122668-A1 COMBINED INHIBITION OF AMINO ACID TRANSPORTERS FOR INHIBITING HUMAN PLASMACYTOID DENDRITIC CELL ACTIVITY DURING AUTOIMMUNITY MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2022-06-16 WO disclosed
EP-4008330-A1 COMBINED INHIBITION OF AMINO ACID TRANSPORTERS FOR INHIBITING HUMAN PLASMACYTOID DENDRITIC CELL ACTIVITY DURING AUTOIMMUNITY Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2022-06-08 EP disclosed
US-11344515-B2 5-hydroxytryptamine 1B receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation INSTITUT PASTEUR (FR) 2022-05-31 US disclosed
EP-1436271-B3 PHENYL-PIPERAZINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS H LUNDBECK AS (DK) 2022-04-20 EP disclosed
EP-3377051-B1 5-HYDROXYTRYPTAMINE 1B RECEPTOR-STIMULATING AGENT FOR ENHANCING IN VIVO ENGRAFTMENT POTENTIAL PASTEUR INSTITUT (FR) 2022-03-30 EP disclosed
US-20210330863-A1 5-HYDROXYTRYPTAMINE 1B RECEPTOR-STIMULATING AGENT FOR ENHANCING IN VIVO ENGRAFTMENT POTENTIAL UNIVERSITÉ PARIS CITÉ (FR) 2021-10-28 US disclosed
US-20210276966-A1 Phenyl-Piperazine Derivatives As Serotonin Reuptake Inhibitors H. LUNDBECK A/S (DK) 2021-09-09 US disclosed
US-11013830-B2 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential INSTITUT PASTEUR (FR) 2021-05-25 US disclosed
WO-2005007144-A2 METHOD OF DIAGNOSIS AND TREATMENT FOR ASTHMA BASED ON HAPLOTYPE ASSOCIATION DECODE GENETICS EHF (IS) 2005-01-27 WO disclosed
US-20050014740-A1 Phenyl-piperazine derivatives as serotonin reuptake inhibitors H. LUNDBECK A/S (DK) 2005-01-20 US disclosed
CN-1561336-A Phenyl-piperazine derivatives as serotonin reuptake inhibitors LUNDBECK & CO AS H (DK) 2005-01-05 CN disclosed
WO-2004096761-A1 AROMATIC OXYPHENYL AND AROMATIC SULFANYLPHENYL DERIVATIVES H. LUNDBECK A/S (DK) 2004-11-11 WO disclosed
EP-1458689-A1 ARYLOXYPHENYL AND ARYLSULFANYLPHENYL DERIVATIVES H. LUNDBECK A/S (DK) 2004-09-22 EP disclosed
EP-1436271-A1 PHENYL-PIPERAZINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS H. Lundbeck A/S (DK) 2004-07-14 EP disclosed
WO-2003064428-A1 FURANO- AND THIENOPYRIMIDINES AS NEUROKINASE INHIBITORS H. LUNDBECK A/S (DK) 2003-08-07 WO disclosed
WO-2003053942-A1 ARYLOXYPHENYL AND ARYLSULFANYLPHENYL DERIVATIVES H. LUNDBECK A/S (DK) 2003-07-03 WO disclosed
WO-2003029232-A1 PHENYL-PIPERAZINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS H. LUNDBECK A/S (DK) 2003-04-10 WO disclosed